Mid wall fibrosis on CMR with late gadolinium enhancement may predict prognosis for LVAD and transplantation risk in patients with newly diagnosed dilated cardiomyopathy—preliminary observations from a high‐volume transplant centre

Patients with newly diagnosed dilated cardiomyopathy (DCM) and advanced heart failure have a very high morbidity and mortality with an unpredictable clinical course. We investigated the role of cardiovascular magnetic resonance (CMR) imaging using late gadolinium enhancement (LGE) in this cohort of high‐risk patients. We hypothesized that LGE has high prognostic value in primary DCM patients referred for possible transplantation/left ventricular assist device (LVAD) consideration.

[1]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[2]  L. Mulligan,et al.  Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. , 2012, Journal of the American College of Cardiology.

[3]  J. Pepper,et al.  Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. , 2011, Journal of the American College of Cardiology.

[4]  F. Leyva,et al.  Myocardial scarring following chemotherapy for multiple myeloma detected using late gadolinium hyperenhancement cardiovascular magnetic resonance. , 2010, Journal of cardiovascular medicine.

[5]  H. Kestler,et al.  Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy , 2009, European heart journal.

[6]  S. Flamm,et al.  Myocardial viability and revascularization. , 2009, Heart failure clinics.

[7]  Katherine C. Wu,et al.  Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. , 2008, Journal of the American College of Cardiology.

[8]  Evrim B Turkbey,et al.  Role of Cardiac Magnetic Resonance Imaging in Assessment of Nonischemic Cardiomyopathies , 2008, Topics in magnetic resonance imaging : TMRI.

[9]  M. Gutberlet,et al.  Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. , 2008, Radiology.

[10]  N. Kelekis,et al.  Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. , 2007, Arthritis and rheumatism.

[11]  S. Iliceto,et al.  Contrast-enhanced cardiovascular magnetic resonance in primary and ischemic dilated cardiomyopathy , 2007, Journal of cardiovascular medicine.

[12]  C. Rochitte,et al.  Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. , 2007, Journal of the American College of Cardiology.

[13]  C. Opasich,et al.  Contrast-enhanced cardiac magnetic resonance in a patient with chemotoxic cardiomyopathy. , 2007, Journal of cardiovascular medicine.

[14]  D. Bluemke,et al.  Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: Current applications and future perspectives , 2006, Heart Failure Reviews.

[15]  Dudley J Pennell,et al.  Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[16]  D. Mozaffarian,et al.  The Seattle Heart Failure Model: Prediction of Survival in Heart Failure , 2006, Circulation.

[17]  Udo Sechtem,et al.  Cardiovascular Magnetic Resonance Assessment of Human Myocarditis: A Comparison to Histology and Molecular Pathology , 2004, Circulation.

[18]  Dipan J. Shah,et al.  Gadolinium Cardiovascular Magnetic Resonance Predicts Reversible Myocardial Dysfunction and Remodeling in Patients With Heart Failure Undergoing &bgr;-Blocker Therapy , 2003, Circulation.

[19]  C H Lorenz,et al.  Differentiation of Heart Failure Related to Dilated Cardiomyopathy and Coronary Artery Disease Using Gadolinium‐Enhanced Cardiovascular Magnetic Resonance , 2003, Circulation.

[20]  R. Kim,et al.  Visualization of presence, location, and transmural extent of healed Q-wave and non–Q-wave myocardial infarction , 2001 .

[21]  Edwin Wu,et al.  Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction , 2001, The Lancet.

[22]  O. Simonetti,et al.  The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. , 2000, The New England journal of medicine.

[23]  R H Hruban,et al.  Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. , 2000, The New England journal of medicine.

[24]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[25]  D. Collett.  Modelling Survival Data in Medical Research , 1994 .

[26]  William T. Abraham,et al.  Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .

[27]  W. D. Ray.  4. Modelling Survival Data in Medical Research , 1995 .